Samsung Biologics breaks ground on Super Plant, the world's largest and most innovative bio-manufacturing facility

INCHEON, South Korea, Nov. 18, 2020 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) officially began construction of its Plant 4 in Incheon,South Korea. Dubbed the "Super Plant," the new, multi-story 238,000-square-meter construction will be the world's largest biopharmaceutical manufacturing ...

2020-11-18 20:00 636

Samsung Biologics announces strategic manufacturing partnership with Lilly to accelerate delivery of COVID-19 antibody treatments

INDIANAPOLIS and INCHEON, South Korea, Nov. 17, 2020 /PRNewswire/ -- Samsung Biologics' partnership with Eli Lilly and Company is expected to greatly accelerate the global supply for Lilly's COVID-19 antibody therapies through a long-term manufacturing agreement, with the ultimate goal of making ...

2020-11-17 20:00 521

Samsung Biologics' Virtual Exhibition Hall earns top industry award for digital creativity and innovation

INCHEON, South Korea, Oct. 4, 2020 /PRNewswire/ -- Samsung Biologics' Virtual Exhibition Hall was recently recognized for its highly interactive digital capabilities and virtual reality (VR) technology to connect with clients around the world. The company's experiential platform won the Best Digi...

2020-11-04 20:00 833

Samsung Biologics and Checkpoint Therapeutics Expand Manufacturing Partnership for Cosibelimab

INCHEON, South Korea and NEW YORK, Nov. 2, 2020 /PRNewswire/ -- Samsung Biologics Co., Ltd. ("Samsung Biologics") (KRX: 207940.KS) and Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ: CKPT), today announced the expansion of a long-term manufacturing partnership for Checkpoint's anti-PD-L1 an...

2020-11-02 20:00 3281

Samsung Biologics Establishes Partnership with China Biotech GeneQuantum Healthcare to Collaborate on ADC Development

INCHEON, South Korea and SUZHOU, China, Nov. 1, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) has entered into a strategic partnership with GeneQuantum Healthcare, a China biotech company, to jointly develop an antibody drug conjugate (ADC) for the treatment of non-small-cell lung carcinoma ...

2020-11-02 08:27 558

Samsung Biologics expands global footprint with opening of new San Francisco CDO R&D Center

INCHEON, South Korea and SAN FRANCISCO, Oct. 28, 2020 /PRNewswire/ -- At a virtual ceremony today, Samsung Biologics (KRX: 207940.KS) announced the grand opening of its first US CDO R&D Center inSan Francisco, bringing its contract development services closer to global clients. As the "Next Door ...

2020-10-29 08:38 5530

Samsung Biologics' strategic business operations continue to support strong third quarter earnings

INCHEON, South Korea, Oct. 21, 2020 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) maintained steady financial results for its fiscal 2020 third quarter endingSeptember 30, demonstrating confident execution of its ongoing business operations. The Company recorded strong revenues of KRW 274.6...

2020-10-21 19:00 7173

Samsung Biologics inks development partnership with Dinona for potential COVID-19 treatment

INCHEON, South Korea, Oct. 20, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) has entered into a partnership agreement with biotech Dinona, further expanding its CDO capabilities to provide a full scope of its development services from cell line development, process development, to non-clini...

2020-10-20 19:00 8159

Samsung Biologics partners with BioEleven for cancer immunotherapy development and manufacturing

INCHEON, South Korea, Oct. 19, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) has entered into a partnership agreement with BioEleven to develop and manufacture BN-101A, a third-generation immunotherapy to treat cancer. Under this agreement, Samsung Biologics will provide a full scope of its ...

2020-10-19 19:00 8778

Samsung Biologics signs strategic partnership with Kanaph Therapeutics to develop treatment for retinal diseases

INCHEON, South Korea, Sept. 23, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) and Kanaph Therapeutics have entered into a strategic partnership to develop KNP-301, a bi-specific Fc fusion protein intended to treat retinal diseases. According to Kanaph Therapeutics, KNP-301 is designed to ta...

2020-09-24 08:00 806

Samsung Biologics and AstraZeneca forge strategic manufacturing partnership for global supply

INCHEON, South Korea, Sept. 21, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) and AstraZeneca announced a long-term supply agreement, valued at approximately $330.8 million. Under this agreement, Samsung Biologics will provide large-scale commercial manufacturing for drug substance in its Pla...

2020-09-22 07:00 11559

Samsung Biologics signs development agreement with Panolos for solid tumor treatment

INCHEON, South Korea, Sept. 16, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) has entered into a service agreement with Panolos Bioscience to develop PB101, an Fc-fusion protein intended to treat solid tumors. Under this agreement, Samsung Biologics will provide a full scope of its developm...

2020-09-17 08:43 1109

Samsung Biologics launches S-CHOice cell line expression technology

INCHEON, South Korea, Aug. 4, 2020 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) today held an online ceremony to announce the launch of its proprietary cell line technology, S-CHOice. Samsung Biologics Pro...

2020-08-05 09:09 1797

Samsung Biologics Posts Strong Second Quarter Earnings With 48.5% Increase In Sales

INCHEON, South Korea, July 21, 2020 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) announced today strong financial results for its fiscal 2020 second quarter endingJune 30, 2020, maintaining steady business performance with a high operating margin at 26.4%.

2020-07-21 20:20 15716

Samsung Biologics Expands Drug Product Manufacturing Facility in Incheon

SONGDO, South Korea, July 20, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) announced a plan to expand its Drug Product (DP) capability in line with increasing market demand and to ensure flexible production capabilities for new and existing clients.

2020-07-21 10:13 15293

Samsung Biologics and ImmuneOncia sign multi-product development and manufacturing agreement

SONGDO, South Korea, July 15, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) and ImmuneOncia Therapeutics held a signing ceremony today for a contract to develop and manufacture five candidate molecules, expanding upon the two companies' existing CDO partnership first established in 2018. ...

2020-07-15 13:46 876

Samsung Biologics signs additional development and manufacturing agreement with STCube

SONGDO, South Korea, July 11, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) has further expanded its partnership with STCube through an additional development and manufacturing service agreement of STM418, an anti-PD1 immuno-oncology candidate. STM418 received much attention from the biopha...

2020-07-12 08:00 975

Samsung Biologics Unveils Virtual Exhibition Hall to Digitally Connect with Clients at BIO 2020

SONGDO, South Korea, June 8, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) announced the launch of a Virtual Exhibition Hall, coinciding with the opening of BIO Digital 2020 week. As the biopharmaceutical industry's largest event, BIO International Convention brings together over 17,000 indu...

2020-06-08 19:00 499

GSK partners with Samsung Biologics to secure additional manufacturing capacity for innovative biopharmaceutical portfolio

LONDON and SONGDO, South Korea, May 21, 2020 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Samsung Biologics (207940.KS) have entered into a partnership to provide GSK with additional capacity to manufacture and supply GSK's innovative biopharmaceutical therapies. Under the terms of th...

2020-05-22 07:11 5682

Samsung Biologics Expands Business Continuity Excellence with Additional ISO22301 Certification

SONGDO, South Korea, May 19, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) announced it has attained ISO22301 certification for additional business operations, demonstrating its unsurpassed commitment to ensuring client satisfaction and operational excellence through its world-class business...

2020-05-20 07:11 1039